Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Links shared publicly online about this topic.

1,167
total visits

Intellipharmaceutics announces dismissal of patent litigation settlement on Focalin XR drug

Intellipharmaceutics International Inc. and its wholly owned subsidiary Intellipharmaceutics Corp. today announced that it and its licensee and development partner Par Pharmaceutical, Inc. ("Par") have received confirmation that the previously announced stays of the patent litigation concerning a generic version of Novartis' Attention Deficit Hyperactivity Disorder drug, Focalin XR®, (dexmethylphenidate hydrochloride), have expired without regulatory intervention, and that the par

View full resource at news-medical.net

Tags: ADHD, ADHD Medication, Disease and Condition, Drug, Pharma, Focalin, Litigation